Salarius Pharmaceuticals Inc (SLRX) News

Salarius Pharmaceuticals Inc (SLRX): $2.99

0.49 (-14.08%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

D

Add SLRX to Watchlist
Sign Up

Filter SLRX News Items

SLRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest SLRX News From Around the Web

Below are the latest news stories about SALARIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SLRX as an investment opportunity.

SLRX Continues Work as it Seeks Alternatives

By Brad Sorensen, CFA NASDAQ:SLRX READ THE FULL SLRX RESEARCH REPORT Earnings Update • Salarius (NASDAQ:SLRX) announced a 3Q loss of $0.65 per share, compared to a $6.41 per share loss in the same quarter in 2022. • Cash and cash equivalents were $7.6 million at the end of 3Q, compared to $12.1 million at the end of 2022. Update Salarius Pharmaceuticals recently announced that it was exploring

Yahoo | November 10, 2023

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8 months Future development activities were identified; Salarius intends to submit an amended Ewing sarcoma clinical trial protocol HOUSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that it participated in a Type B End-of-Phase 2 (EOP2) meeting with th

Yahoo | November 7, 2023

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug clearance from FDA Company to explore strategic alternatives and implement measures to extend its resources HOUSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new

Yahoo | August 10, 2023

SLRX Pursuing Strategic Alternatives

By Brad Sorensen, CFA NASDAQ:SLRX READ THE FULL SLRX RESEARCH REPORT Salarius Pharmaceuticals (NASDAQ:SLRX) recently announced that it was exploring “strategic alternatives” and cutting costs in order to extend its resources. We are disappointed in this announcement as we continue to believe in the science behind the treatments being developed by Salarius. However, we understand that funding has

Yahoo | August 9, 2023

Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources

HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced plans to explore strategic alternatives and implement measures to extend its resources. “The second quarter and recent weeks were highlighted by significant advancements in both of our development programs, but after a review o

Yahoo | August 8, 2023

SLRX Continues Cancer Fight with Phase I Trial Approval

By Brad Sorensen, CFA NASDAQ:SLRX READ THE FULL SLRX RESEARCH REPORT • Salarius (NASDAQ:SLRX) announced that it has received FDA clearance of SP-3164 Investigational New Drug Application (NDA) to begin a Phase I clinical trial in relapsed/refractory Non-Hodgkin Lymphoma patients. o SP-3164 is explained in more detail below, but this novel targeted protein degrader is one of the compounds being

Yahoo | July 11, 2023

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

The trial will assess the safety and preliminary efficacy of Salarius’ novel targeted protein degrader SP-3164; Patient dosing expected to begin in 2H 2023 The trial will also assess the utility of a gene signature to identify patients that are potentially sensitized to SP-3164 treatment and may be more likely to respond HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degrada

Yahoo | July 11, 2023

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care agent lenalidomideHOUSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the presentation of a poster related to the company’s novel molecular glue, SP-3164, at the Europ

Yahoo | June 12, 2023

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it has closed its previously announced private placement for the issuance and sale of an aggregate of 3,636,364 shares of its common stock (or common stock equivalents in lieu thereof), Series A-1 warrants to purchase up to

Yahoo | May 16, 2023

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 3,636,364 shares of its common stock (or common stock equivalents in lieu thereof), Series A-1 warrants to purchase up to an aggregate o

Yahoo | May 12, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!